Open AccessImmunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor
Author(s) -
Archana Asundi,
Yvonne Robles,
Tyler Starr,
Alan Landay,
Jennifer Kinslow,
Joshua Ladner,
Laura F. White,
Rebeca Plank,
Kathleen Melbourne,
Daniel S. Weisholtz,
Monica L Bennett,
Hong Pan,
Emily Stern,
Alexander Lin,
Daniel R. Kuritzkes,
Nina Lin
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002079
Subject(s) - efavirenz , oxidative stress , glutamate receptor , medicine , immunology , biology , pharmacology , endocrinology , viral load , virus , receptor , antiretroviral therapy
The biological mechanisms by which efavirenz (EFV) causes central nervous system (CNS) effects are unclear. The objective of this pilot study was to elucidate the mechanisms underlying these CNS effects by correlating well-described neuropsychological (NP) changes with neurometabolites and immunologic markers following switch off EFV.